Arthrogen is an Amsterdam based biopharmaceutical company developing local gene therapy for inflammatory diseases, using viral mediated gene transfer. The first target indication is in the field of rheumatic diseases. The therapeutic vectors are derived from natural occurring adeno-associated viruses (AAV) that are not pathogenic in humans. The recombinant viruses are engineered to express therapeutic proteins or to express genes that can knock-down proteins that are involved in the pathogenesis of rheumatic diseases. Arthrogen BV was founded in 2005 as a joint venture between the Dubai Bone & Joint Center (DBAJ) in the United Arab Emirates and the Academic Medical Center (AMC) in Amsterdam, the Netherlands. Arthrogen’s aim is to develop adeno-associated viral mediated gene therapy for patients with rheumatic conditions. The company is based on the premises of the AMC/University of Amsterdam in Amsterdam.
View Top Employees from Arthrogen BVWebsite | http://www.arthrogen.nl |
Revenue | $6 million |
Employees | 22 (22 on RocketReach) |
Founded | 2005 |
Phone | +31 20 566 2648 |
Industry | Business Services General, Biopharma, Business Services, Biotechnology, Health Care, Science and Engineering |
Web Rank | 8 Million |
Keywords | Arthrogen |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 541713 Companies |
Looking for a particular Arthrogen BV employee's phone or email?
The Arthrogen BV annual revenue was $6 million in 2024.
Piet Bruijnzeel is the Chief Medical Officer of Arthrogen BV.
22 people are employed at Arthrogen BV.
Arthrogen BV is based in Holland, North Brabant.
The NAICS codes for Arthrogen BV are [54, 5417, 541, 54171, 541713].
The SIC codes for Arthrogen BV are [873, 87].